A Randomized, Single Blind, Consecutive Enrollment Evaluation of The Elixir Novolimus-Eluting Coronary Stent System With Durable Polymer Compared to the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions and a Non-Randomized, Consecutive Enrollment Evaluation of the Elixir Novolimus-Eluting Coronary Stent System With Bioabsorbable Polymer Compared to Contemporary Controls in the Treatment of Patients With De Novo Native Coronary Artery Lesions.

Next Previous
Trial Profile

A Randomized, Single Blind, Consecutive Enrollment Evaluation of The Elixir Novolimus-Eluting Coronary Stent System With Durable Polymer Compared to the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions and a Non-Randomized, Consecutive Enrollment Evaluation of the Elixir Novolimus-Eluting Coronary Stent System With Bioabsorbable Polymer Compared to Contemporary Controls in the Treatment of Patients With De Novo Native Coronary Artery Lesions.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 29 Jul 2017

At a glance

  • Drugs Novolimus (Primary) ; Zotarolimus
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Registrational; Therapeutic Use
  • Acronyms EXCELLA-II
  • Sponsors Elixir Medical Corporation

    • Most Recent Events

    • 02 Apr 2015 Status changed from active, no longer recruiting to completed, according to final results presented at the 26th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
    • 09 Feb 2015 Planned End Date changed from 1 Jul 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 03 Sep 2013 Results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top